Cha바카라 사이트man Jung-Jin Seo outlines mergers, investments, and strategic goals.
During an Investor Relations (IR) presentation on August 24th, Chairman Jung-Jin Seo of the 바카라 사이트 Group provided insight into the company's merger plans to South Korean institutional and retail investors.
Chairman Seo elucidated, "The decision to pursue this merger has arisen from investor demand. Once the ongoing 바카라 사이트 healthcare absorption merger concludes, we will proceed with the merger of 바카라 사이트 Pharmaceutical. Our agenda also includes evaluating the possibility of listing 바카라 사이트 Holdings, and should surplus capital be available, we are poised to expand our stake."
The announcement of the merger between 바카라 사이트 and 바카라 사이트 Healthcare was made on August 17th. Chairman Seo emphasized the phased approach of the "step-by-step merger" strategy, encompassing the consolidation of 바카라 사이트, 바카라 사이트 Healthcare, and 바카라 사이트 Pharmaceutical. He underscored the commitment to channel the united group's resources towards internal drug development, strategic mergers and acquisitions, licensing initiatives, and substantial investments.
In an online IR event, Chairman Seo unveiled the company's strategic foray into digital healthcare investment. Capitalizing on the expanding global digital healthcare market, 바카라 사이트 intends to leverage its clinical expertise, genetic data utilization capabilities, and explore novel business avenues. The slated investment is set to commence in 2023, with a projected commercialization timeline of 3 to 4 years.
Key Highlights from 바카라 사이트’s Online Investor Relations Q&A
①With the biosimilar industry designated as a national strategic technology, how will increased tax deductions for R&D expenses and facility investments impact the company?
A:In Phase 1 clinical trials, we are planning to escalate the tax deduction to 15%. Moreover, Phase 3 trials will see an expansion from 30% to 40%. This translates to an anticipated tax deduction benefit of approximately to million (20 to 30 billion won) for R&D-intensive companies like ours.
② By when do you foresee an increase in the dividend payout ratio, and are there additional shareholder return strategies aside from dividends?
A:Our objective is to enhance the cash dividend payout ratio by at least 2024, striving to reach a short-term target of 30% dividend ratio.
③Are there plans to develop treatments for diabetes and obesity, which are currently of high interest?
A:Absolutely, we are actively engaged in the development of a peptide-based treatment for obesity.
④ Is the overseas trip by Cha바카라 사이트man Seo and Vice Cha바카라 사이트man in early September exclusively related to 바카라 사이트 for the merger, or does it aim to attract new investments?
A:Our visit holds dual purposes of corporate 바카라 사이트 and d바카라 사이트ect business engagement. Our itinerary covers Japan, Singapore, the United States, and Canada. Notably, in the United States, we will convene all employees for comprehensive updates, performance reports, and strategic discussions. In Canada, we have planned extensive engagement with about 800 physicians, with Vice Cha바카라 사이트man Hyoung-Ki Kim holding separate meetings. Additionally, our Canadian subsidiary's CEO will meet with a substantial number of individuals.
⑤The projected future revenue of the merged entity does not include the digital healthcare sector. What are the plans in this area?
A: Our investments in the digital medical device sector are oriented towards the future. Despite existing uncertainties, we are committed to sustained investment over the next 2 to 3 years, commencing this year. The anticipated timeline for commercialization is approximately 3 to 4 years. Our approach encompasses in-house investments as well as considerations for strategic M&A.
⑥ How do you envisage achieving billion (12 trillion won) target by 2030?
A: We anticipate that new drug sales, primarily centered around Jimpantra, will contribute around 40% towards the billion objective. The remaining 60% will encompass contributions from our existing biosimilar products and forthcoming offerings.
⑦Truxima's market share in Europe has been modest, and Herzuma's performance has been inconsistent. Could you elucidate the underlying factors?
A: This is largely attributed to initial sales through ind바카라 사이트ect channels for these products. Transitioning to d바카라 사이트ect distribution approximately a year ago has contributed to improved sales performance and growth.
⑧ Could you provide insights into the actual reputation of Remsima SC?
A: Remsima SC is available in Europe, and its prescription outcomes have been extensively presented in medical conferences. Data from these conferences indicate that 77% of patients prescribed 바카라 사이트 products report satisfaction.
⑨ How well-established is 바카라 사이트's international direct distribution network?
A: In the biosimilars field, 바카라 사이트 has solidified its brand presence in Europe. Our plans for the United States involve creating a 300-member strong sales team. While other companies deploy larger sales forces, our lean yet effective direct distribution network has demonstrated efficacy. For instance, in Japan, with a sales team of 60 members, we reach 60% of breast cancer patients requiring prescriptions.
⑩ With Herzuma’s market share in the United States at around 1%, what is the strategic outlook for this product?
A: While considering potential price adjustments, 바카라 사이트's focus is not exclusively on U.S. sales, as Herzuma maintains favorable profit margins in several other countries.